Order Article Reprints

Arora L, Mohan CD, Yang MH, Rangappa S, Deivasigamani A, Kumar AP, Kunnumakkara AB, Garg M, Chinnathambi A, Alharbi SA, et al. Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway. Cancers. 2021; 13(21):5479. https://doi.org/10.3390/cancers13215479

Arora, Loukik, Chakrabhavi Dhananjaya Mohan, Min Hee Yang, Shobith Rangappa, Amudha Deivasigamani, Alan Prem Kumar, Ajaikumar B. Kunnumakkara, Manoj Garg, Arunachalam Chinnathambi, Sulaiman Ali Alharbi, and et al. 2021. "Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway" Cancers 13, no. 21: 5479. https://doi.org/10.3390/cancers13215479

Arora, L., Mohan, C. D., Yang, M. H., Rangappa, S., Deivasigamani, A., Kumar, A. P., Kunnumakkara, A. B., Garg, M., Chinnathambi, A., Alharbi, S. A., Alahmadi, T. A., Rangappa, K. S., Hui, K. M., Sethi, G., & Ahn, K. S. (2021). Tris(dibenzylideneacetone)dipalladium(0) (Tris DBA) Abrogates Tumor Progression in Hepatocellular Carcinoma and Multiple Myeloma Preclinical Models by Regulating the STAT3 Signaling Pathway. Cancers, 13(21), 5479. https://doi.org/10.3390/cancers13215479